S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
NASDAQ:TCRR

TCR2 Therapeutics Stock Forecast, Price & News

$5.24
-0.39 (-6.93%)
(As of 11/26/2021 04:00 PM ET)
Add
Compare
Today's Range
$5.13
$5.54
50-Day Range
$5.24
$9.48
52-Week Range
$5.13
$35.86
Volume
318,987 shs
Average Volume
538,019 shs
Market Capitalization
$200.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.15
30 days | 90 days | 365 days | Advanced Chart
Receive TCRR News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


TCR2 Therapeutics logo

About TCR2 Therapeutics

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It also involves in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle in May 2015 and is headquartered in Cambridge, MA.

Headlines

Analyst Ratings For TCR2 Therapeutics
October 21, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCRR
Fax
N/A
Employees
118
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$8.02 per share

Profitability

Net Income
$-67.12 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
28,972,000
Market Cap
$200.27 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
11/26/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/10/2022

MarketRank

Overall MarketRank

2.58 out of 5 stars

Medical Sector

78th out of 1,392 stocks

Biological Products, Except Diagnostic Industry

9th out of 201 stocks

Analyst Opinion: 4.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












TCR2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions

Is TCR2 Therapeutics a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TCR2 Therapeutics stock.
View analyst ratings for TCR2 Therapeutics
or view top-rated stocks.

How has TCR2 Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

TCR2 Therapeutics' stock was trading at $8.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TCRR shares have decreased by 38.9% and is now trading at $5.24.
View which stocks have been most impacted by COVID-19
.

Are investors shorting TCR2 Therapeutics?

TCR2 Therapeutics saw a drop in short interest during the month of October. As of October 29th, there was short interest totaling 1,300,000 shares, a drop of 15.0% from the October 14th total of 1,530,000 shares. Based on an average daily trading volume, of 778,700 shares, the days-to-cover ratio is currently 1.7 days. Currently, 3.6% of the company's shares are sold short.
View TCR2 Therapeutics' Short Interest
.

When is TCR2 Therapeutics' next earnings date?

TCR2 Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for TCR2 Therapeutics
.

How were TCR2 Therapeutics' earnings last quarter?

TCR2 Therapeutics Inc. (NASDAQ:TCRR) issued its earnings results on Wednesday, November, 10th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.06.
View TCR2 Therapeutics' earnings history
.

What price target have analysts set for TCRR?

10 Wall Street analysts have issued 1-year price objectives for TCR2 Therapeutics' shares. Their forecasts range from $7.00 to $55.00. On average, they anticipate TCR2 Therapeutics' share price to reach $28.20 in the next year. This suggests a possible upside of 438.2% from the stock's current price.
View analysts' price targets for TCR2 Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are TCR2 Therapeutics' key executives?

TCR2 Therapeutics' management team includes the following people:
  • Garry E. Menzel, President, Chief Executive Officer & Director
  • Mayur Ian Somaiya, Chief Financial Officer
  • Robert Hofmeister, Chief Scientific Officer
  • Alfonso Quintás-Cardama, Chief Medical Officer
  • Peter Olagunju, Chief Technical Officer

What other stocks do shareholders of TCR2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

When did TCR2 Therapeutics IPO?

(TCRR) raised $76 million in an IPO on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is TCR2 Therapeutics' stock symbol?

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Who are TCR2 Therapeutics' major shareholders?

TCR2 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.76%), Wellington Management Group LLP (7.19%), ArrowMark Colorado Holdings LLC (3.18%), Geode Capital Management LLC (1.19%), Rothschild & Co. Asset Management US Inc. (0.91%) and Two Sigma Investments LP (0.84%). Company insiders that own TCR2 Therapeutics stock include Mayur Ian Somaiya, Morana Jovan-Embiricos, Neil W Gibson and Robert Hofmeister.
View institutional ownership trends for TCR2 Therapeutics
.

Which major investors are selling TCR2 Therapeutics stock?

TCRR stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Rothschild & Co. Asset Management US Inc., Dimensional Fund Advisors LP, Goldman Sachs Group Inc., Altium Capital Management LP, Squarepoint Ops LLC, Citigroup Inc., and Two Sigma Advisers LP.
View insider buying and selling activity for TCR2 Therapeutics
or view top insider-selling stocks.

Which major investors are buying TCR2 Therapeutics stock?

TCRR stock was acquired by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, Marshall Wace LLP, ArrowMark Colorado Holdings LLC, Caas Capital Management LP, Caption Management LLC, Trexquant Investment LP, Two Sigma Investments LP, and Oppenheimer & Co. Inc..
View insider buying and selling activity for TCR2 Therapeutics
or or view top insider-buying stocks.

How do I buy shares of TCR2 Therapeutics?

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TCR2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $5.24.

How much money does TCR2 Therapeutics make?

TCR2 Therapeutics has a market capitalization of $200.27 million. The company earns $-67.12 million in net income (profit) each year or ($2.46) on an earnings per share basis.

How many employees does TCR2 Therapeutics have?

TCR2 Therapeutics employs 118 workers across the globe.

What is TCR2 Therapeutics' official website?

The official website for TCR2 Therapeutics is www.tcr2.com.

Where are TCR2 Therapeutics' headquarters?

TCR2 Therapeutics is headquartered at 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142.

How can I contact TCR2 Therapeutics?

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at (617) 949-5200 or via email at [email protected].


This page was last updated on 11/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.